e-learning
resources
Virtual 2020
Tuesday, 08.09.2020
Reflections from the Lung Science 2020 conference
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Itaconate controls the severit of pulmonary fibrosis
P. Ogger (London, United Kingdom)
Source:
Virtual Congress 2020 – Reflections from the Lung Science 2020 conference
Session:
Reflections from the Lung Science 2020 conference
Session type:
Symposium
Number:
4691
Disease area:
-
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Ogger (London, United Kingdom). Itaconate controls the severit of pulmonary fibrosis. Virtual Congress 2020 – Reflections from the Lung Science 2020 conference
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease
Year: 2011
Itaconate drives the resolution of pulmonary fibrosis
Source: ERS Lung Science Conference 2020
Year: 2020
The impact of emphysema in pulmonary fibrosis
Source: Eur Respir Rev 2013; 22: 153-157
Year: 2013
The effect of interferon-γ on bleomycin-induced alveolitis and pulmonary fibrosis in rats
Source: Eur Respir J 2005; 26: Suppl. 49, 81s
Year: 2005
Pharmacometabolic response to pirfenidone in pulmonary fibrosis detected by MALDI-FTICR-MSI
Source: Eur Respir J, 52 (3) 1702314; 10.1183/13993003.02314-2017
Year: 2018
Macitentan reduces progression of TGF-ß1-induced pulmonary fibrosis and pulmonary hypertension
Source: Eur Respir J, 52 (2) 1701857; 10.1183/13993003.01857-2017
Year: 2018
Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2006 - Clinical physiology
Year: 2006
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018
Mortality in combined pulmonary fibrosis and emphysema patients is determined by the sum of pulmonary fibrosis and emphysema
Source: ERJ Open Res, 7 (3) 00316-2021; 10.1183/23120541.00316-2021
Year: 2021
Inhibition of local fibrinolysis differs between idiopathic pulmonary fibrosis (IPF) and fibrotic non-specific interstitial pneumonia (f-NSIP)
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009
Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis
Source: Eur Respir J 2012; 39: 359-365
Year: 2012
Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2015 – IPF pathogenesis
Year: 2015
Pirfenidone in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 36: 695-696
Year: 2010
Pirfenidone in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 35: 821-829
Year: 2010
New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung
Source: International Congress 2015 – Inflammation and remodelling in lung disease
Year: 2015
Cyclo-oxygenase (Cox)-2 is not upregulated in idiopathic pulmonary fibrosis
Source: Eur Respir J 2001; 18: Suppl. 33, 410s
Year: 2001
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Pulmonary arterial hypertension in combined pulmonary emphysema and fibrosis
Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy
Year: 2005
17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept